Abbott Laboratories (NYSE:ABT) has been positively trending with
rising financial strength as reported by AE Wealth Management LLC that recently acquired many shares. The stock is considered an attractive investment among large-cap MedTech companies despite occasional underperformance. An analyst from
Piper Sandler sees
Abbott as an attractive entry point, and the company is deemed a strong bet despite market losses. Its promising
diabetes and
cancer divisions have driven interest, with the dividend growth potential appealing to many investors. Despite some bearish moves, Abbott is nearing a key technical benchmark, and its
segment performance continues to improve. Despite a drop in COVID-19 testing revenue, other areas, including innovative
obesity treatments, grew, boosting annual profit guidance. Company's fundamentals remain solid with diversified business and strong focus on scaling innovations. Nonetheless, the stock experienced a dip after a jury ordered Abbott to pay $495 million in a baby formula case. Still, the company's core businesses thrived and Abbott posted strong Q1 earnings, despite this setback. Overall, the dividend potential, along with strong innovation and fundamentals make
Abbott Laboratories an attractive long-term investment.
Abbott Laboratories ABT News Analytics from Wed, 24 Jan 2024 08:00:00 GMT to Sun, 22 Sep 2024 09:37:41 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor -3
